Pardes Biosciences to Present at Jefferies Global Healthcare Conference
Pardes Biosciences, Inc. (NASDAQ: PRDS) has announced management's participation in a fireside chat at the Jefferies Global Healthcare Conference on June 9, 2022, at 8:30 a.m. PT / 11:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pardes Biosciences, Inc. (NASDAQ: PRDS) has announced management's participation in a fireside chat at the Jefferies Global Healthcare Conference on June 9, 2022, at 8:30 a.m. PT / 11:30 a.m. ET. The event will focus on the company's development of PBI-0451, a novel oral antiviral drug aimed at treating and preventing SARS-CoV-2 infections, including COVID-19. A live audio webcast will be accessible through Pardes' website, with an archived replay available for 30 days post-event.
Details
News Market Reaction – PRDS
The recorded move for PRDS in the trading session of this news was +1.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022 at 8:30 a.m. PT / 11:30 a.m. ET.
A live audio webcast of the fireside chat will be available in the Investors section of Pardes’ website at www.pardesbio.com, with an archived replay available for 30 days following the event.
About Pardes Biosciences, Inc.
Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates. For more information, please visit www.pardesbio.com.
Availability of Other Information about Pardes Biosciences
Pardes Biosciences intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Pardes Biosciences’ Investors website, in addition to following Pardes’ press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.
Investor Contacts:
Patrick O'Brien
pobrien@pardesbio.com
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.